Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Accent Therapeutics Presents Data Supporting Two Lead Programs at AACR 2024 Annual Meeting | ||
By: PR Newswire Association LLC. - 08 Apr 2024 | Back to overview list |
|
Robert A. Copeland, Chief Scientific Officer, to provide major symposium presentation on inhibition of key RNA-modifying enzymes as precision cancer therapeutics Preclinical data validate DHX9 as a new target in breast cancer and other solid tumors with loss-of-function mutations in the DNA damage repair genes BRCA1 or BRCA2 Accent shares data on KIF18A, an exciting target in chromosomally instable tumors, showing their novel inhibitors display selective dose-dependent tumor growth inhibition Preclinical data validate circBRIP1 as a minimally-invasive, pharmacodynamic biomarker of DHX9 inhibition LEXINGTON, Mass., April 8, 2024 /PRNewswire/ -- Accent Therapeutics, a biopharmaceutical company pioneering a novel class of small molecule precision cancer therapeutics presents advances in cancer targeting, including data on DHX9 and KIF18A inhibitor activity in multiple tumor types, at the 2024 American Association for Cancer Research (AACR) Annual Meeting, taking place April 5-10 in San Diego, California. "Accent has expanded the potential of our two lead programs in preclinical investigations, and we are excited for the promise they hold for addressing cancers with high unmet clinical need," said Robert A. Copeland, Ph.D., President, Founder, and Chief Scientific Officer of Accent Therapeutics. "Our results reveal that DHX9 and KIF18A inhibition are potent therapeutic strategies that stand to benefit large patient populations. These findings validate our systematic approach to tapping the rich therapeutic potential of our target space." In the presentation entitled "RNA-Modifying Enzyme Inhibitors as Precision Cancer Therapeutics," Dr. Copeland delineates the promise of RNA-modifying enzyme (RME) inhibitors as precision cancer therapeutics that confer cancer-selective growth inhibition in vitro and in vivo. The potential of RME inhibitors is exemplified by inhibitors of the novel cancer target, DHX9, which display great promise as a novel treatment modality in BRCA1 and/or BRCA2 loss-of-function (LOF) cancers across multiple tumor types, including breast cancers. Studies in breast cancer models demonstrate the potential impact of DHX9 inhibitor treatment for patients with defective DNA repair. These data are highlighted in a presentation entitled "DHX9 inhibition as a novel therapeutic for cancer with loss-of-function mutations in DNA damage repair genes BRCA1 and BRCA2." Additional key takeaways from this talk are:
Accent scientists further reinforce KIF18A – a kinesin that plays a critical role in facilitating mitosis – as a compelling therapeutic target in chromosomally instable tumors. In a poster entitled "Inhibition of KIF18A leads to mitotic arrest and robust anti-tumor activity in chromosomally instable tumors," they show data that Accent's novel, potent and selective small molecule inhibitors of KIF18A:
Data describing a DHX9-specific pharmacodynamic biomarker of inhibition are presented in a poster entitled "circBRIP1 RNA as a non-invasive target engagement pharmacodynamic biomarker for DHX9 inhibition." Key takeaways include:
Select posters and presentations will be shared on Accent's website following the meeting. About DHX9 About KIF18A About Accent Therapeutics View original content to download multimedia:https://www.prnewswire.com/news-releases/accent-therapeutics-presents-data-supporting-two-lead-programs-at-aacr-2024-annual-meeting-302110786.html SOURCE Accent Therapeutics, Inc. |
||
|
||
Copyright 2024 PR Newswire Association LLC. | Back to overview list |